Recursion Pharmaceuticals, Inc

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a clinical-stage TechBio company focused on transforming drug discovery through the integration of biology and technology. Its proprietary Recursion Operating System (OS) leverages a broad array of technologies to explore and interpret trillions of biological and chemical interactions within the expansive Recursion Data Universe. By combining physical experiments with digital modeling in iterative feedback loops—blending laboratory work ("atoms") with computational analysis ("bits")—the company efficiently scales data generation in biology and chemistry. This integrated approach enables rapid validation of computer-generated hypotheses and accelerates the discovery of novel therapeutic compounds.

• Clinical Pipeline Progress and Key Efficacy Results: In 2024, Recursion made significant progress across its clinical pipeline, reporting promising early efficacy and safety results for two investigational therapies. REC-617, a CDK7 inhibitor optimized via its AI platform, demonstrated encouraging Phase 1/2 outcomes including a durable partial response in a patient with metastatic ovarian cancer and stable disease in four patients with other solid tumors. Additionally, REC-994, an oral superoxide scavenger targeting cerebral cavernous malformations (CCM), showed robust safety and reductions in lesion volume in a Phase 2 trial, with data highlighted during the 2025 International Stroke Conference. Further progression of REC-994 will be guided by upcoming regulatory discussions and long-term data.
• Clinical Trial Expansions and Regulatory Milestones: Recursion continued to build momentum in 2024 by initiating three new clinical studies: DAHLIA (REC-1245 for advanced solid tumors and lymphoma), TUPELO (REC-4881 for familial adenomatous polyposis), and ALDER (REC-3964 for recurrent C. difficile infections). Other pipeline advancements included regulatory clearances for REC-4539 (an LSD1 inhibitor for small cell lung cancer), CTA approval for REC-3565 (a MALT1 inhibitor for B-cell malignancies), and progress of REC-4209 for idiopathic pulmonary fibrosis into IND-enabling studies. These advancements reflect Recursion’s commitment to accelerating novel therapeutic programs.
• Strategic Partnerships and Milestone Achievements: In 2024, Recursion achieved multiple partnership milestones, yielding $45 million in aggregate cash inflows. Collaborations with Roche and Genentech led to the development of advanced whole-genome phenomaps, including the first CRISPR knockout map in neural iPSC cells, resulting in Roche exercising a $30 million option. Recursion also progressed two early-stage programs under its Sanofi collaboration, generating $15 million. Meanwhile, Bayer utilized Recursion's OS for 25 oncology data packages and adopted its LOWE AI workflow, and an ongoing alliance with Merck KGaA continued to drive innovation in oncology and immunology target discovery.
• Platform Innovations and Technology Integration: Recursion’s technology platform evolved significantly in 2024, especially with the integration of Exscientia’s Centaur precision chemistry platform following the business combination. The full-stack Recursion OS was employed in over 10 design cycles, identifying hit compounds across seven immune-relevant targets. Enhancements to AI-powered synthesis, protein-target mapping, phenomics, and transcriptomics capabilities enabled industrial-scale experimentation. The launch of BioHive-2, the most powerful supercomputer in biopharma, powered the training of advanced foundation models including Phenom-2, MolPhenix, MolGPS, and MolE—pushing the boundaries of predictive modeling and structure-based drug discovery.
• Emergence of ClinTech and Operational Streamlining: The company deepened its investment in clinical technology (“ClinTech”), leveraging AI and real-world data to enhance patient stratification, streamline clinical workflows, and reduce trial initiation costs. This includes efforts in small cell lung cancer trials using Tempus data and automation of site engagement processes. Recursion also announced the carve-out of its Austrian operations into Alpha Biotechnology GmbH, where it will retain 49% ownership. Furthermore, the company is actively reducing its real estate footprint and consolidating operations as part of a broader cost moderation and operational focus strategy post-merger.
• Financial Performance and Outlook: For the year ended December 31, 2024, Recursion reported total revenue of $58.8 million, up from $44.6 million in 2023, driven largely by collaboration milestone payments. On a pro forma basis, assuming the Exscientia merger from the beginning of 2023, revenue reached $82.6 million. The company ended 2024 with $603 million in cash and maintains a projected runway into 2027. However, research and development and general and administrative expenses increased notably, contributing to a net loss of $463.7 million for the year. The company remains on track to achieve $100 million in synergies from the Exscientia transaction, with the majority of the benefits expected in 2025.

Technical Observation (on the daily chart):

RXRX is showing early signs of a potential recovery after a sharp decline earlier in 2025. The stock is trading above its 21-day moving average ($5.21), suggesting short-term bullish momentum, but remains below the 50-day MA ($6.37), indicating the medium-term trend is still bearish. RSI is neutral at 51.57, with rising volume hinting at accumulation. A break above the 50-day MA would strengthen the bullish case, while support holds around $5.20 and resistance lies near $6.37 and $7.50.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Speculative Buy’ rating has been given to Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) at the current market price of USD 5.78 as of April 29,2025 at 08:05 AM PDT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is April 29,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.